Anavex Life Sciences Corp (AVXL)

[tredenwater2]

Thanks for the reminder Bio. Patience is hard and sometimes we get a glimpse of the size of the iceberg as it ever so slightly bobs in the water but with the majority of the iceberg still submerged (hidden behind the cloak of secrecy for competitive advantages) we sit and wait. Two things stand out to me in the last 5 years part of which you covered in your post. One, the drug is not disease specific. By carefully correcting calcium imbalance and oxidative stress in the brain it gives an enormous amount of repair possibilities back to the bodies own healing process giving its application a larger field than say even ibuprofen for pain. Two, this is big! like others have mentioned you just dont rush to market with the first indication. Dr Missling started with Alzheimer’s possibly because of the time needed and complexity of the disease and has also chosen to drag Parkinsons into the mix based on data gleaned from the first Ph 2a.
All I know is that every DRUG biomarker we find(like the slides have shown) our chances for approval dramatically increase!

Good luck